Priovant Therapeutics Inc.

Address: 151 West 42nd Street Floor 15

Sponsor Overview

assignment

Specializations

Inflammatory muscle disease

Priovant Therapeutics Inc. is involved in clinical research for dermatomyositis, with a focus on adult patients affected by this rare autoimmune myopathy. The sponsor’s work in this area centers on treatment options for muscle weakness, skin involvement, and broader inflammatory disease activity.

Dermatomyositis
Autoimmune myopathy
Inflammation-related muscle impairment

The company’s clinical activity in this field reflects interest in therapies that address complex systemic inflammation and functional decline associated with idiopathic inflammatory myopathies.

Non-infectious ocular inflammation

The sponsor also supports research in active non-infectious uveitis, including intermediate uveitis, posterior uveitis, and panuveitis. This area of interest involves immune-mediated inflammation within the eye, where preserving vision and controlling inflammatory activity are central therapeutic goals.

Intermediate uveitis
Posterior uveitis
Panuveitis

Its research portfolio in ocular disease is directed toward conditions that can lead to chronic visual disturbance and require sustained control of intraocular inflammation.

Immune-mediated disease therapeutics

Across both studied conditions, Priovant Therapeutics Inc. concentrates on immune-mediated inflammatory disorders that affect distinct organ systems. The therapeutic focus spans systemic and tissue-specific disease manifestations, linking muscle and ocular inflammation within a broader autoimmune research context.

Systemic immune dysregulation
Tissue-specific inflammatory disease
Autoimmune intervention

The sponsor’s clinical interests are aligned with therapies intended to reduce inflammatory burden in rare and difficult-to-treat autoimmune conditions.

Trial Name	Country	Status
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Brepocitinib in Adults with Dermatomyositis	Belgium Bulgaria Czechia Germany Hungary Italy Poland Portugal Romania Slovakia Spain The Netherlands	Not Recruiting
Phase 3 Randomized, Double-Masked, Placebo-Controlled Trial of Brepocitinib Tosilate in Adults with Active Non-Infectious Intermediate, Posterior, and Panuveitis	Austria Belgium Czechia Germany Greece Hungary Italy Poland Spain	Not Recruiting